Update on clinical research on nephrology in 2021

doi:10.3877/cma.j.issn.2095-3216.2022.02.006

Abstract

Abstract:

This article reviewed the important advances in the clinical research field of nephrology in 2021, which included primary glomerular disease, secondary glomerular disease, acute kidney injury, chronic kidney disease-mineral and bone abnormalities, and kidney injury associated with COVID-19, etc, involving their risks of occurrence and progression, diagnosis, treatment, and prognosis, in order to provide ideas and help for the clinical diagnosis and treatment.

Key words: Kidney disease, Clinical research, Progress, Diagnosis, Treatment, Prognosis

Ting Li, Ling Jiang, Luhan Geng, Zhimin Huang, Yanggang Yuan, Bo Zhang, Ningning Wang, Li Zhang, Huijuan Mao, Changying Xing. Update on clinical research on nephrology in 2021[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2022, 11(02): 84-89.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2022.02.006

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2022/V11/I02/84

References 61

[1]	Wang YN, Zhou XJ, Chen P, et al. Interaction between GALNT12 and C1GALT1 associates with galactose-deficient IgA1 and IgA nephropathy [J]. J Am Soc Nephrol, 2021, 32(3): 545-552.
[2]	Dotz V, Visconti A, Lomax-Browne HJ, et al. O- and N-glycosylation of serum immunoglobulin A is associated with IgA nephropathy and glomerular function [J]. J Am Soc Nephrol, 2021, 32(10): 2455-2465.
[3]	Wheeler DC, Toto RD, Stefansson BV, et al. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy [J]. Kidney Int, 2021, 100(1): 215-224.
[4]	Xie D, Zhao H, Xu X, et al. Intensity of macrophage infiltration in glomeruli predicts response to immunosuppressive therapy in patients with IgA nephropathy [J]. J Am Soc Nephrol, 2021, 32(12): 3187-3196.
[5]	Canney M, Barbour SJ, Zheng Y, et al. Quantifying duration of proteinuria remission and association with clinical outcome in iga nephropathy [J]. J Am Soc Nephrol, 2021, 32(2): 436-447.
[6]	Sethi S, Madden B, Debiec H, et al. Protocadherin 7-associated membranous nephropathy [J]. J Am Soc Nephrol, 2021, 32(5): 1249-1261.
[7]	Al-Rabadi LF, Caza T, Trivin-Avillach C, et al. Serine protease HTRA1 as a novel target antigen in primary membranous nephropathy [J]. J Am Soc Nephrol, 2021, 32(7): 1666-1681.
[8]	Caza TN, Hassen SI, Kuperman M, et al. Neural cell adhesion molecule 1 is a novel autoantigen in membranous lupus nephritis [J]. Kidney Int, 2021, 100(1): 171-181.
[9]	Fernandez-Juarez G, Rojas-Rivera J, Logt AV, et al. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy [J]. Kidney Int, 2021, 99(4): 986-998.
[10]	Scolari F, Delbarba E, Santoro D, et al. Rituximab or cyclophosphamide in the treatment of membranous nephropathy: the RI-CYCLO randomized trial [J]. J Am Soc Nephrol, 2021, 32(4): 972-982.
[11]	Zonozi R, Laliberte K, Huizenga NR, et al. Combination of rituximab, low-dose cyclophosphamide, and prednisone for primary membranous nephropathy: a case series with extended follow up [J]. Am J Kidney Dis, 2021, 78(6): 793-803.
[12]	Delafosse M, Ponlot E, Esteve E, et al. Personalized phospholipase A2 receptor antibody-driven rituximab treatment strategy in membranous nephropathy [J]. Kidney Int, 2021, 99(4): 1023-1024.
[13]	Haukka J, Sandholm N, Valo E, et al. Novel linkage peaks discovered for diabetic nephropathy in individuals with type 1 diabetes [J]. Diabetes, 2021, 70(4): 986-995.
[14]	Anderson AH, Xie D, Wang X, et al. Novel risk factors for progression of diabetic and nondiabetic CKD: findings from the chronic renal insufficiency cohort (CRIC) study [J]. Am J Kidney Dis, 2021, 77(1): 56-73.
[15]	Schrauben SJ, Shou H, Zhang X, et al. Association of multiple plasma biomarker concentrations with progression of prevalent diabetic kidney disease: findings from the chronic renal insufficiency cohort (CRIC) study [J]. J Am Soc Nephrol, 2021, 32(1): 115-126.
[16]	Wheeler DC, Stefánsson BV, Jongs N, et al. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial [J]. Lancet Diabetes Endocrinol, 2021, 9(1): 22-31.
[17]	Heerspink HJL, Jongs N, Chertow GM, et al. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial [J]. Lancet Diabetes Endocrinol, 2021, 9(11): 743-754.
[18]	Jongs N, Greene T, Chertow GM, et al. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial [J]. Lancet Diabetes Endocrinol, 2021, 9(11): 755-766.
[19]	Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in patients with diabetes and chronic kidney disease [J]. N Engl J Med, 2021, 384(2): 129-139.
[20]	Heerspink HJL, Kohan DE, de Zeeuw D. New insights from sonar indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction [J]. Kidney Int, 2021, 99(2): 346-349.
[21]	Ravindran A, Casal Moura M, Fervenza FC, et al. In patients with membranous lupus nephritis, exostosin-positivity and exostosin-negativity represent two different phenotypes [J]. J Am Soc Nephrol, 2021, 32(3): 695-706.
[22]	Rovin BH, Teng YKO, Ginzler EM, et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial [J]. Lancet, 2021, 397(10289): 2070-2080.
[23]	Atisha-Fregoso Y, Malkiel S, Harris KM, et al. Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis [J]. Arthritis Rheumatol, 2021, 73(1): 121-131.
[24]	Rovin BH, Furie R, Teng YKO, et al. A secondary analysis of the belimumab international study in lupus nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis [J]. Kidney Int, 2021, 101(2): 403-413.
[25]	Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/vasculitis foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis [J]. Arthritis Rheumatol, 2021, 73(8): 1366-1383.
[26]	Jayne DRW, Merkel PA, Schall TJ, et al. Avacopan for the treatment of ANCA-associated vasculitis [J]. N Engl J Med, 2021, 384(7): 599-609.
[27]	Gulati K, Edwards H, Prendecki M, et al. Combination treatment with rituximab, low-dose cyclophosphamide and plasma exchange for severe antineutrophil cytoplasmic antibody-associated vasculitis [J]. Kidney Int, 2021, 100(6): 1316-1324.
[28]	Nasr SH, Fidler ME, Said SM, et al. Immunofluorescence staining for immunoglobulin heavy chain/light chain on kidney biopsies is a valuable ancillary technique for the diagnosis of monoclonal gammopathy-associated kidney diseases [J]. Kidney Int, 2021, 100(1): 155-170.
[29]	Javaugue V, Pascal V, Bender S, et al. RNA-based immunoglobulin repertoire sequencing is a new tool for the management of monoclonal gammopathy of renal (kidney) significance [J]. Kidney Int, 2021, 101(2): 331-337.
[30]	Zand L, Rajkumar SV, Leung N, et al. Safety and efficacy of daratumumab in patients with proliferative GN with monoclonal immunoglobulin deposits [J]. J Am Soc Nephrol, 2021, 32(5): 1163-1173.
[31]	Nasr SH, Kudose SS, Said SM, et al. Immunotactoid glomerulopathy is a rare entity with monoclonal and polyclonal variants [J]. Kidney Int, 2021, 99(2): 410-420.
[32]	Mohammad KN, Chan EYY, Lau SY, et al. Relationship between acute kidney injury, seasonal influenza, and environmental factors: a 14-year retrospective analysis [J]. Environ Int, 2021, 153: 106521.
[33]	Ikizler TA, Parikh CR, Himmelfarb J, et al. A prospective cohort study of acute kidney injury and kidney outcomes, cardiovascular events, and death [J]. Kidney Int, 2021, 99(2): 456-465.
[34]	Hapca S, Siddiqui MK, Kwan RSY, et al. The relationship between AKI and CKD in patients with type 2 diabetes: an observational cohort study [J]. J Am Soc Nephrol, 2021, 32(1): 138-150.
[35]	Wilson FP, Martin M, Yamamoto Y, et al. Electronic health record alerts for acute kidney injury: multicenter, randomized clinical trial [J]. BMJ, 2021, 372: m4786.
[36]	Lodise TP, Drusano G. Vancomycin area under the curve-guided dosing and monitoring for adult and pediatric patients with suspected or documented serious methicillin-resistant staphylococcus aureus infections: putting the safety of our patients first [J]. Clin Infect Dis, 2021, 72(9): 1497-1501.
[37]	Lee JD, Heintz BH, Mosher HJ, et al. Risk of acute kidney injury and clostridioides difficile infection with piperacillin/tazobactam, cefepime, and meropenem with or without vancomycin [J]. Clin Infect Dis, 2021, 73(7): e1579-e1586.
[38]	Espi M, Teuma C, Novel-Catin E, et al. Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study [J]. Eur J Cancer, 2021, 147: 29-39.
[39]	Gupta S, Short SAP, Sise ME, et al. Acute kidney injury in patients treated with immune checkpoint inhibitors [J]. J Immunother Cancer, 2021, 9(10): e003467.
[40]	Lunyera J, Clare RM, Chiswell K, et al. Racial differences in aki incidence following percutaneous coronary intervention [J]. J Am Soc Nephrol, 2021, 32(3): 654-662.
[41]	Mehran R, Owen R, Chiarito M, et al. A contemporary simple risk score for prediction of contrast-associated acute kidney injury after percutaneous coronary intervention: derivation and validation from an observational registry [J]. Lancet, 2021, 398(10315): 1974-1983.
[42]	Gaudry S, Hajage D, Martin-Lefevre L, et al. Comparison of two delayed strategies for renal replacement therapy initiation for severe acute kidney injury (AKIKI 2): a multicentre, open-label, randomised, controlled trial [J]. Lancet, 2021, 397(10281): 1293-1300.
[43]	Liu C, Peng Z, Dong Y, et al. Continuous renal replacement therapy liberation and outcomes of critically ill patients with acute kidney injury [J]. Mayo Clin Proc, 2021, 96(11): 2757-2767.
[44]	Naorungroj T, Neto AS, Murugan R, et al. Continuous renal replacement therapy: the interaction between fluid balance and net ultrafiltration [J]. Am J Respir Crit Care Med, 2021, 203(9): 1199-1201.
[45]	Roberts JA, Joynt GM, Lee A, et al. The effect of renal replacement therapy and antibiotic dose on antibiotic concentrations in critically ill patients: data from the multinational sampling antibiotics in renal replacement therapy study [J]. Clin Infect Dis, 2021, 72(8): 1369-1378.
[46]	Pergola PE, Rosenbaum DP, Yang Y, et al. A randomized trial of tenapanor and phosphate binders as a dual-mechanism treatment for hyperphosphatemia in patients on maintenance dialysis (AMPLIFY) [J]. J Am Soc Nephrol, 2021, 32(6): 1465-1473.
[47]	Hill Gallant KM, Stremke ER, Trevino LL, et al. EOS789, a broad-spectrum inhibitor of phosphate transport, is safe with an indication of efficacy in a phase 1b randomized crossover trial in hemodialysis patients [J]. Kidney Int, 2021, 99(5): 1225-1233.
[48]	Isaka Y, Hamano T, Fujii H, et al. Optimal phosphate control related to coronary artery calcification in dialysis patients [J]. J Am Soc Nephrol, 2021, 32(3): 723-735.
[49]	Ogata H, Fukagawa M, Hirakata H, et al. Effect of treating hyperphosphatemia with lanthanum carbonate vs calcium carbonate on cardiovascular events in patients with chronic kidney disease undergoing hemodialysis: the landmark randomized clinical trial [J]. JAMA, 2021, 325(19): 1946-1954.
[50]	Chan L, Chaudhary K, Saha A, et al. AKI in hospitalized patients with COVID-19 [J]. J Am Soc Nephrol, 2021, 32(1): 151-160.
[51]	Gupta S, Coca SG, Chan L, et al. AKI treated with renal replacement therapy in critically ill patients with COVID-19 [J]. J Am Soc Nephrol, 2021, 32(1): 161-176.
[52]	De Meester J, De Bacquer D, Naesens M, et al. Incidence, characteristics, and outcome of COVID-19 in adults on kidney replacement therapy: a regionwide registry study [J]. J Am Soc Nephrol, 2021, 32(2): 385-396.
[53]	Hsu CM, Weiner DE, Aweh G, et al. COVID-19 among US dialysis patients: risk factors and outcomes from a national dialysis provider [J]. Am J Kidney Dis, 2021, 77(5): 748-756.
[54]	May RM, Cassol C, Hannoudi A, et al. A multi-center retrospective cohort study defines the spectrum of kidney pathology in coronavirus 2019 disease (COVID-19) [J]. Kidney Int, 2021, 100(6): 1303-1315.
[55]	Diao B, Wang C, Wang R, et al. Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 infection [J]. Nat Commun, 2021, 12(1): 2506.
[56]	Govind D, Becker JU, Miecznikowski J, et al. Podosighter: a cloud-based tool for label-free podocyte detection in kidney whole-slide images [J]. J Am Soc Nephrol, 2021, 32(11): 2795-2813.
[57]	Ginley B, Jen KY, Han SS, et al. Automated computational detection of interstitial fibrosis, tubular atrophy, and glomerulosclerosis [J]. J Am Soc Nephrol, 2021, 32(4): 837-850.
[58]	Schena FP, Anelli VW, Trotta J, et al. Development and testing of an artificial intelligence tool for predicting end-stage kidney disease in patients with immunoglobulin A nephropathy [J]. Kidney Int, 2021, 99(5): 1179-1188.
[59]	Zhang K, Liu X, Xu J, et al. Deep-learning models for the detection and incidence prediction of chronic kidney disease and type 2 diabetes from retinal fundus images [J]. Nat Biomed Eng, 2021, 5(6): 533-545.
[60]	Chan L, Nadkarni GN, Fleming F, et al. Derivation and validation of a machine learning risk score using biomarker and electronic patient data to predict progression of diabetic kidney disease [J]. Diabetologia, 2021, 64(7): 1504-1515.
[61]	Ayoub I, Wolf BJ, Geng L, et al. Prediction models of treatment response in lupus nephritis [J]. Kidney Int, 2022, 101(2): 379-389.

Please choose a citation manager

Content to export